Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
Status:
Unknown status
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the efficacy of AKR963 compared to placebo and active
comparator in lowering fasting triglyceride levels in patients with very high fasting
triglyceride levels ≥ 500 and ≤ 1500 mg/dL.